Small, specific audiences where volume marketing does not work.
Rare disease companies serve a genuinely small, specific patient and prescriber population, which means generic high-volume marketing tactics fail entirely and the digital presence has to be built around precision reach instead.
A rare condition may have only a few hundred or a few thousand patients globally, and the prescribers treating it are a specialist minority. Search volume is low by design, and success looks like reaching the specific specialists and patients who actually exist, not broad visibility.
Content built for depth over volume, connections to patient advocacy and specialist networks, and diagnosis-journey content helping someone reach the right specialist faster in a category where delayed diagnosis is a real problem.
Our content and platforms are designed to complement the work patient advocacy organisations already do, not substitute for medical advice or take over a role that belongs with them.
The scope our work with rare disease companies has operated within.
The build priorities for a small, specific audience differ from a mass-market condition. Here is what rare disease companies most often need.
How this work is approached specifically for Rare Disease.
What comes up when building for a rare disease company.
We map the specific diagnosing centres, genetic testing pathways and specialist societies this population moves through, rather than targeting a broad demographic. With eligible patients sometimes numbering only in the low thousands worldwide, content succeeds by being complete and precise for every relevant clinician, geneticist and caregiver rather than reaching widely, and it is built around the exact clinical terms this small, highly informed audience searches for.
We build content and platforms designed to work alongside patient advocacy organisations rather than duplicate their role, since these groups are often the first and most trusted source a newly diagnosed family turns to. That means linking clearly to existing advocacy resources, referencing their patient registries where relevant, and leaving disease education and emotional support to the organisations already doing that work well.
Precision channels reach this audience more effectively than broad campaigns, since the treating specialists for a rare condition are often a few hundred clinicians worldwide rather than a general practitioner population. Programmatic HCP advertising lets us target by exact specialty, sub-specialty and even institution, so budget goes toward the small number of physicians who diagnose and treat the condition directly instead of a wide, wasted reach.
Patient support programmes for rare conditions can be built around individual case management rather than the tiered, high-volume support models common in larger disease areas, because the enrolled population is small enough for that level of attention. The patient support programme website is built to support that closer relationship — tracking individual patient journeys, caregiver needs and specialist referrals rather than routing everyone through a generic call-centre flow.
Related sectors worth reviewing alongside rare disease.
A small, specific audience that generic marketing volume cannot reach. Tell us your condition and we will tell you how we would approach it for a rare disease company.